The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).
 
Rahul Raj Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; EcoR1 Capital; Exelixis; Janssen; Jubilant Pharmaceuticals; Merck; Novartis; OncLive.; PCCTC; Pfizer; Tersera
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology
 
Sylvie Rottey
Research Funding - Amgen (Inst); Ipsen (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Ghent University Hospital (Inst)
 
Alice Bernard-Tessier
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Novartis (Inst); Orion Clinical; Roche
Travel, Accommodations, Expenses - AAA/Endocyte/Novartis; Bayer; Orion Clinical
 
Begoña Mellado-Gonzalez
No Relationships to Disclose
 
Takeo Kosaka
No Relationships to Disclose
 
Walter Michael Stadler
Leadership - EMA Wellness
Stock and Other Ownership Interests - Fortress Biotech
Consulting or Advisory Role - AstraZeneca; Bayer; Calico; CVS Caremark; Merck; Pfizer; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst); Xencor (Inst)
Expert Testimony - Apotex; Sandoz
Other Relationship - American Cancer Society; UpToDate
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Brian Yu
Employment - Amgen
 
Crystal Shaw
Employment - Amgen
 
Chia-Hsin Ju
Employment - Amgen
 
Corbin Thompson
Employment - Amgen
 
Ana Aparicio
Honoraria - American Cancer Society; Amgen; Astellas Pharma; AstraZeneca; Biosense Webster (I); Boston Scientific (I); Daiichi Sankyo Inc; Janssen Research & Development
Consulting or Advisory Role - American Cancer Society; Amgen; Astellas Pharma; AstraZeneca; Biosense Webster (I); Boston Scientific (I); Daiichi Sankyo Inc.; Janssen Research & Development
Speakers' Bureau - Biosense Webster (I); Boston Scientific (I)
Research Funding - BioSense Webster (I); Boston Scientific (I); Bristol-Myers Squibb (Inst); Hansen Medical (I); Janssen (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Two (I)
Travel, Accommodations, Expenses - Biosense WEbster (I)